

Directory of UK Biopharma Companies



**INNOVATION
IS
GREAT**
BRITAIN & NORTHERN IRELAND

Cb = pH[
7.403.98
7.602.51
8.001.00
8.403.98
8.801.58
9.001.00
9.403.98
9.801.58

Biopharma

Introduction to this directory

The UK is one of the best locations in the world to discover and develop biotechnology and pharmaceutical products. We offer leading-edge research and talent, established platforms for technology development and clinical trials, an unrivalled data capability through the NHS for research and innovation, a culture of collaboration, and a launch pad to global markets with world-renowned regulatory expertise and standards.

More than 2,000 companies operate in the UK biopharma sector, either core businesses developing their own products or one of the many value-adding services and supply companies that support the industry.

This directory is illustrative rather than complete. It profiles a range of organisations that are active and looking for international partners. **Contact lifescience@trade.gov.uk for more information.**

Segmentation of this directory

Antibiotics

MGB Biopharma
NovaBiotics
Oxford University Innovation
Polypharmakos
Summit Therapeutics

Cancer Research

Cancer Research UK

Cardiovascular, Respiratory and Metabolic Disease

LifeArc
Oxford University Innovation
Therakind
Vectura
Yaqrit

Autoimmune, Inflammatory and Orphan Disease

C4X Discovery
Capella Bioscience
Domainex
LifeArc
Mironid
Norgine
Oxford University Innovation
Sareum
Sentinel
Therakind
Vernalis

Cancer: General Oncology

Bicycle Therapeutics
Edinburgh Molecular Imaging
EstryX Pharma
Institute of Cancer Research
LifeArc
Opal Oncology
Oxford University Innovation
PhoreMost
Sareum

Cancer: Immune Oncology

Adaptimmune
Biosceptre
F-star
Fusion Antibodies
Immunocore
Institute of Cancer Research
Karus Therapeutics
Kymab
pHion Therapeutics
PsiOxus
Redx Pharma
Therakind
Vasgen

Drug Delivery

Apconix
Crystec Pharma
Enesi
LifeArc
Midatech Pharma
Nanomerics
pHion Therapeutics
Quay Pharma
Therakind
Warwick Ventures
Xenetic

Genetics, Genomics and Gene Therapy

Congenica
Kinomica
Nanogenics
Oxford Biomedica
Phion Therapeutics
Silence Therapeutics
Touchlight
Valirx

Infectious Disease and Virology

iQur
LifeArc
Nova Biotics
Oxford University Innovation
pHion Therapeutics
ReViral
Virion Biotherapeutics Ltd
Warwick Ventures

Central Nervous System

Autifony Therapeutics
Cholestenix
Chronos Therapeutics

**Regenerative Medicine,
Medical Devices and Software**

Institute of Cancer Research
Locate Therapeutics
Overwatch Research
Oxford University Innovation

Multiple Therapeutic Areas


Abcodia
Biogelx
Crystec Pharma
Exploristics
Fora Health
Fusion Antibodies
Hikma Pharmaceuticals
HYPHA Discovery
ILLINGWORTH Research Group
Institute of Cancer Research
Kinomica
LifeArc
National Institute for Health Research
Overwatch Research
Quay Pharma
Randox
Remap
Sonrai Analytics
Sygnature Discovery
SYNthesis Research

Diagnostics

Biosignatures
Kinomica
Oxford Brain Diagnostics
ProAxis
Randox
Warwick Ventures

Contact lifescience@trade.gov.uk
for introductions

Antibiotics

Name	About	Assets
 MGB Biopharma <i>Delivering Novel Anti-Infectives</i> www.mgb-biopharma.com	<p>Keywords: Antibiotics, Clostridium Difficile, CDAD.</p> <p>Description: A clinical-stage company developing a novel class of compounds that targets Clostridium difficile-associated diarrhea (CDAD), and various preclinical stage compounds targeting multi-drug resistant bacterial and fungal infections.</p>	<p>MGB-BP-3, oral for C. diff, Phase II, seeking partners.</p> <p>MGB-BP-3, IV for MRSA, VRE, and streptococcus, pre-clinical.</p> <p>MGB-BP-3, topical, pre-clinical Various discovery - stage compounds for Gram-negative bacteria, anti-fungal, anti-viral and anti-parasitic.</p>

NovaBiotics®

www.novabiotics.co.uk

Keywords:
Anti-infectives, Antibacterial and antifungal therapies, MDR infections, Gram-negative bacterial infections cystic fibrosis, Onychomycosis, Aspergillosis.

Description:
NovaBiotics is a leading AMR focused, clinical- stage company developing antibacterial and antifungal therapies from its novel AMR focused technology platforms that have been engineered from components of the innate immune response to infection.

NovaBiotics has three advanced product candidates in clinical development (Lynovex, Novexatin, Luminaderm) for difficult to treat bacterial and fungal infections, plus.

Earlier stage compounds for MDR bacterial Gram negative infections, MRSA, aspergillosis, candidemia, cryptococcosis.

Therapeutic candidates have been developed from two novel AMR focused platforms based on innate immune antimicrobial peptides and cysteamine.





www.innovation.ox.ac.uk

Keywords:
MRSA, Infectious endocarditis, SSSI.

Description:
Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

First-in-class antibiotic that provides a clear commercial advantage and is supported by novel chemistry and a data package, based on a two-year SAR program.

More information on our technologies can be found at:
<https://innovation.ox.ac.uk/technologies-available>

Name	About	Assets
 <p data-bbox="73 352 328 376">www.polypharmakos.com</p>	<p data-bbox="381 272 689 368">Keywords: Antimicrobials, Natural products, Plants, Fungi, AMR, Novel mechanisms of action.</p> <p data-bbox="381 392 654 608">Description: A natural product screening and drug development company from the University of Cambridge and the Royal Botanic Gardens, Kew, focused on the discovery of novel antimicrobial agents and extracts.</p>	<p data-bbox="712 272 997 464">Intelligent screening of major collections worldwide with particular emphasis on the identification and rapid characterization of new antimicrobial hits especially those operating through novel mechanisms of action.</p>
 <p data-bbox="73 815 281 839">www.summitplc.com</p>	<p data-bbox="381 655 645 751">Keywords: New mechanism antibiotics, C.difficile infection, Gonorrhoea, ESKAPE.</p> <p data-bbox="381 775 689 1182">Description: A leader in antibiotic innovation, Summit's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for a range of infections including ridinilazole for the treatment of C. difficile infection and SMT-571 for the treatment of gonorrhoea. Summit is using its proprietary Discuva Platform to expand their pipeline.</p>	<p data-bbox="712 655 1020 871">Ridinilazole (SMT19969), a first-in-class, oral selective antibiotic for C. difficile infection, demonstrated superiority over vancomycin on sustained clinical response in Phase II CoDiFy POC trial. Progressing into Phase III. Global rights available under Summit IPRs.</p>

Autoimmune, Inflammatory and Orphan Disease

Name	About	Assets
------	-------	--------



C4X Discovery
A new dimension in drug discovery

www.c4xdiscovery.com

Keywords:

Small molecule drug discovery engine, Inflammatory diseases, Diabetes, Cancer, Addiction, 3D ligand conformation, Novel target identification, Conformetrix, Taxonomy3, Molplex, Small molecules, Drug discovery.

Description:

C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting its cutting-edge technologies Taxonomy3, Molplex and Conformetrix to design.

Orexin-1 Antagonist for addictive disorders, Nrf-2 activator for inflammatory diseases including COPD, Small molecule anti-IL-17 inhibitor, Small molecule GLP-1 agonist for diabetes, GPR142 agonist for diabetes.



CAPELLA
BIOSCIENCE

www.capellabioscience.com

Keywords:

Therapeutic monoclonal antibodies for autoimmune disease and oncology, Monoclonal antibodies, Inflammation, Autoimmune, Intestinal bowel disease, Scleroderma, Fibrosis, Oncology, Immuno-oncology.


Description:

Capella Bioscience uses novel technologies to identify and develop monoclonal antibodies directed at innovative targets in autoimmune disease and oncology.

CBS001: Clinical candidate antibody in IND-enabling studies targeting a TNFSF protein for treatment of IBD.

CBS004: Preclinical antibody for treatment of scleroderma.

CBS007: Tumor specific monoclonal antibody to a checkpoint inhibitor target.

Name	About	Assets
 <p>Domainex Enrich your medicines pipeline</p> <p>www.domainex.co.uk</p>	<p>Keywords: Protein expression & structural biology combinatorial domain hunting: unlocking challenging targets assay biology (biochemical, biophysical and cellular) FBDD incorporating MST and GCI/SPR integrated medicinal chemistry incorporating SBDD lysine methyltransferase lead compounds.</p> <p>Description: Domainex is an integrated drug discovery service company generating high quality results and IP on behalf of our pharma, biotech and academic clients based around the globe.</p>	<p>G9a inhibitors with oral bioavailability and in vivo efficacy in a number of solid tumour models are available for out-licensing.</p>



www.lifearc.org


Keywords:
Methylation, Epigenetics, Crohn's disease, Inflammatory bowel disease epigenetic signature.

Description:
LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.


Epigenetic markers for the diagnosis of Crohn's disease. An epigenetic test based on a blood sample provides a diagnosis of Crohn's disease in both pediatric and adult patients.

Name	About	Assets
 <p>www.mironid.com</p>	<p>Keywords: Phosphodiesterase, cAMP, Autosomal dominant polycystic kidney disease, ADPKD, Kidney disease, Inflammatory disease, Psoriasis, Prostate cancer, Orphan diseases, Rare diseases, Ulcerative colitis and inflammatory bowel disease (IBD).</p> <p>Description: Harnessing unique insights into phosphodiesterase biology to develop innovative treatments for orphan and inflammatory diseases.</p>	<p>First in class PDE4 long form activating compounds for the treatment of multiple rare/orphan diseases driven by abnormally elevated cAMP levels, including ADPKD.</p> <p>Next generation of PDE4 short isoform selective inhibitors that avoid the GI side effects induced by pan-PDE4 inhibitors, for the treatment of chronic inflammatory diseases.</p>
 <p>www.norgine.com</p>	<p>Keywords: Inflammation, Preclinical, Inflammatory bowel disease, Chemokine receptor, Gastrointestinal EVASINS, (11805).</p> <p>Description: Leading independent European “go to” specialist pharmaceutical company that has been established for over 100 years and has a presence in all major European markets.</p>	<p>A number of patent protected CCR9 antagonists at the preclinical stage of development that are available for divestment.</p>
 <p>www.innovation.ox.ac.uk</p>	<p>Keywords: Evasins 11805.</p> <p>Description: Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.</p> <p>More information on our technologies can be found at: https://innovation.ox.ac.uk/technologies-available</p>	<p>Small proteins called evasins have been identified from tick saliva. These evasins have a unique ‘one-to-many’ mechanism of action, i.e. they bind multiple chemokines, and potentially block inflammation. These evasins are being evaluated in preclinical models of myocarditis and myocardial infarction, and also acute lung injury.</p>

Name	About	Assets
 <p>www.sareum.com</p>	<p>Keywords: Autoimmune, JAK1, TYK2, Psoriasis, Rheumatoid arthritis, RA, Multiple sclerosis, MS, Lupus, Inflammatory bowel disease, IBD, Oncology, AML, Lymphoma, Immuno-oncology, Cancer immunotherapy.</p> <p>Description: Drug discovery and development company, with a focus on targeted small molecule therapeutics for cancer and autoimmune diseases.</p>	<p>TYK2/JAK1 inhibitor SDC-1801 targeting psoriasis, rheumatoid arthritis, inflammatory bowel disease, lupus and other autoimmune diseases (preclinical).</p> <p>TYK2/JAK1 inhibitor SDC-1802 targeting T-ALL, ALCL, B-cell lymphoma, solid tumours and cancer immunotherapy (preclinical).</p> <p>Aurora+FLT3 kinases inhibitor targeting AML and ALL (preclinical).</p>
 <p>www.sentineloncology.com</p>	<p>Keywords: Small molecule orphan drug, Rare disease, Orphan indication, Drug candidate, Fragile X syndrome.</p> <p>Description: Drug discovery company dedicated to the development of novel drug candidates in areas of high unmet medical need.</p>	<p>SOL784 a candidate drug in development for the treatment of Fragile X Syndrome a rare disease and the largest single genetic cause of autism.</p>
 <p>www.therakind.com</p>	<p>Keywords: Paediatric, Orphan, Geriatric, Drug delivery, Cytotoxic, Oral liquid, Oncology, Chemotherapy, Immunology, Reformulation.</p> <p>Description: Specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Therakind has successfully brought three products to approval in the EU/UK. An extensive pipeline of products is under development.</p>	<p>Therakind developed Jylamvo[®] an EMA authorised oral liquid methotrexate (a cytotoxic oncological/immunosuppressant product). Seeking additional partners for distribution of Jylamvo.</p>


Name	About	Assets
 www.vernalis.com	<p>Keywords: Drug discovery, Small molecules, Fragments, Structure-based drug discovery, Oncology, Immunology, Inflammation, Anti-infectives.</p> <p>Description: Development-stage company focused on products in the therapeutic areas of cough/cold, CNS, oncology, and inflammation.</p>	<p>V158866, for pain, spasticity and other neuro, Phase II.</p> <p>Research collaboration opportunities to apply drug discovery platform to targets from partners.</p>


Cancer Research

Name	About	Assets
 <p>CANCER RESEARCH UK</p> <p>http://commercial.cancerresearchuk.org</p> <p>Licensing Opportunities:</p> <ul style="list-style-type: none"> • Small molecules, biological therapeutics, diagnostics and enabling technologies • Research & development collaborations • Drug discovery alliances • Early phase trial sponsorship and funding • Partnering opportunities 	<p>Keywords: Oncology, R&D collaborations, Clinical development partnerships, Novel cancer targets, Drug discovery, Drug development, Small molecule, biological therapeutics, Preclinical, Clinical, Phase I, Combinations, Precision medicine, Diagnostics, Partnering.</p> <p>Description: CRUK's Commercial Partnerships team is the specialist commercialisation and development arm of Cancer Research UK (CRUK), the world's largest independent funder of cancer research. We have exclusive rights to intellectual property arising from CRUK's annual research spend of \$500M and offer opportunities for licensing and collaboration across a broad spectrum of oncology research, including funding and sponsorship for first-in-human clinical studies on industry-developed therapeutics.</p>	<p>aPKC inhibitor DIB4: clinic stage, ADCC triggering CD19 antibody P53 TCR mimic antibody IKK alpha inhibitor CDK11 inhibitor - novel ADC payload Antibody enhancing technology MRCK inhibitor MSI diagnostic.</p> <p>other opportunities include:</p> <p>Chk2 inhibitor Cdc7 inhibitor CEA antibodies Dvβ6-binding peptides for tumour targeting Dvβ6 antagonistic antibodies TACE antibody CLEC14a LMP2-TCR CCR4 antibodies ADC Portfolio Dvβ6-binding peptides for imaging Optimam mammography image database & viewing software Imaging agent for prostate and glioma tumour detection IBIS software (Tyrer-Cuzick Model) Mutational signatures: whole cancer genome interpretation platform.</p> <p>Clinical Co-development Partnerships Fully funded, pre-clinical/early clinical therapeutic asset co-development through the CRUK Centre for Drug Development, which has a current portfolio of ~20 active programmes. Scope includes GMP manufacture (biologicals and small molecules), conduct of pre-IND studies, regulatory submissions, sponsorship of GCP clinical studies run through a prestigious network of UK sites.</p>

Cancer: General Oncology

Name	About	Assets
 <p>www.bicycletherapeutics.com</p>	<p>Keywords: Bicyclic peptides, Oncology, Research collaboration, Drug discovery.</p> <p>Description: R&D stage company backed by Atlas Ventures and Novartis Venture funding, among others, exploring the therapeutic possibilities of bicyclic peptides.</p>	<p>BT1718 bicyclic oncologic agent (pre-clinical).</p> <p>Research collaboration opportunities to apply proprietary platform to targets from partners.</p>
 <p>Edinburgh Molecular Imaging Ltd.</p> <p>www.emimaging.com</p>	<p>Keywords: Oncology, Radiopharmaceuticals, Systemic radiotherapy, PET Imaging, Optical imaging, Peptides, c-MET.</p> <p>Description: Developing a unique range of radiotherapeutic and imaging agents that enable detection and treatment of c-MET positive cancers.</p>	<p>EMP-100 - A phase I ready systemic radiotherapeutic agent for treating c-MET positive tumours such as Non Small Cell Lung Cancer.</p> <p>EMI-137 - A phase IIb colorectal cancer (CRC) agent - to detect early cancerous lesions in the colon.</p>
 <p>www.stryx.com</p>	<p>Keywords: Oncology, Women's health, Hormone-dependent cancer, Dual aromatase-sulfatase inhibitor, Steroid sulfatase inhibition, Multi-targeting therapeutic, Orally-available.</p> <p>Description: A drug development company focused on the design and development of small molecule therapeutics influencing the estrogen biosynthesis pathway.</p>	<p>Orally active Dual Aromatase-Sulfatase Inhibitor (DASI) for estrogen-dependent tumours.</p>

Name	About	Assets
 <p>The Institute of Cancer Research</p> <p>www.icr.ac.uk</p>	<p>Keywords: Precision medicine, Predictive medicine, Biomarkers, Drug discovery, First-in-human clinical trials, Immuno-oncology, Big data and AI, Antibody-based therapeutics, Pre-clinical tools for testing novel agents, Radiation-combinations, Microscopy, Genomic sequencing, Drug resistance mechanisms, Imaging, Medical physics.</p> <p>Description: The Institute of Cancer Research, London, is a member college of the University of London and one of the world's leading higher education institutions in measures of collaboration and partnership with industry. It is top-ranked for research quality and impact amongst UK universities in the UK Government's definitive measure of research quality and impact - for example, having discovered 20 new drug candidates since 2005 of which 11 have reached clinical trials - and is currently working in collaboration with more than 100 companies to translate its research into new cancer treatments and technologies.</p>	<p>LOX: for the treatment of breast, ovarian and colorectal cancer, inhibitors should prevent tumor progression and metastases (late lead optimization).</p> <p>GDEPT: Gene-directed enzyme pro-drug therapy, for treatment of lung, colorectal, head and neck tumors, as well as hepatoma (pre-clinical).</p>

Name	About	Assets
 <p>www.lifearc.org</p>	<p>Keywords: Immuno-oncology, Immunology, Oncology, Antibodies, Neoplasm, Signaling molecule modulator, Millipore kinase panel, Autophagy cancer, Kidney, Renal cell carcinoma, Tyrosine kinase inhibitors, Diagnostic, Gene profile, Sunitinib, Response cancer, Therapeutic, Pro-drug, Therapeutic, Palladium activated, Endotoxaemia, Ang2, Angiopoietin, Sepsis retinopathy, Src, Abl, Breast cancer, Ovarian cancer.</p> <p>Description: LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.</p>	<p>MNK Inhibitors for out licensing ULK Inhibitors for out licensing PAICS Inhibitors for out licensing.</p> <p>Genetic markers for therapy in renal cell carcinoma (RCC) Provides stratification of renal cell carcinoma to improve patient outcome and therapy options.</p> <p>Targeting cancer therapeutics with palladium-activated compounds.</p> <p>Ang2 specific biotherapeutic.</p> <p>Specific Src inhibitor.</p>




www.opalonc.com

Keywords:
 Oncology, Glioblastoma, Research collaboration, Drug discovery, Small molecule, Brain penetrant.

Description:
 Opal Oncology seek out commercially viable anti cancer therapies in high-impact orphan cancer indications which have been failed by existing therapies.

Proprietary novel approach for the treatment of Glioblastoma Multiforme and other cancer indications. Pre-clinical.

Name	About	Assets
 <p>www.innovation.ox.ac.uk</p>	<p>Keywords: Insulin-like Growth Factor 2, IGF2, IGF2-TRAP, Ewing sarcoma, (15455, 15456).</p> <p>Therapeutic, STSi, CAIX, microtubule, angiogenesis aromatase, 17β-estradiol, DASi.</p> <p>Description: Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.</p> <p>More information on our technologies can be found at: https://innovation.ox.ac.uk/technologies-available/</p>	<p>A novel and specific biomarker on the cell surface of Ewing's Sarcoma tumors that can be used as a diagnostic or therapeutic target.</p> <p>Insulin-like Growth Factor 2 (IGF2) over-expression has been reported in a wide range of cancers. Mutations in domain 11 of IGF2 Receptor increase the affinity of IGF2 to its receptor. These mutated receptors act as a trap for IGF2 (IGF2-TRAP) and have been shown to treat hypoglycaemia and reduce tumour volume in Ewing sarcoma xenograft models.</p> <p>STX140 - an orally active multi-targeting drug for multiple oncology indications, acting as an irreversible steroid sulfatase inhibitor (STSi); a carbonic anhydrase IX (CAIX) inhibitor; a microtubule disruptor; and an angiogenesis inhibitor.</p> <p>Orally active Dual Aromatase-Sulfatase inhibitors (DASI) for treatment of estrogen-dependent cancers.</p>




www.phoremmost.com


Keywords:
Phenotypic drug discovery, PROTEIN-interference technology, First-in-class targets, Collaborative R&D, Out-licensing portfolio.


Description:
PhoreMost is using a proprietary druggable target identification platform called 'Protein Interference' (PROTEINI[®]) to systematically provide first-in-class drug discovery programs for out-licensing to Pharma.



R&D collaborations Pre-clinical stage asset for oncology (AML and mutant KRAS cancers).


Name	About	Assets
 <p data-bbox="73 389 253 411">www.sareum.com</p>	<p data-bbox="381 272 488 293">Keywords:</p> <p data-bbox="381 298 676 464">Autoimmune, JAK1, TYK2, Psoriasis, Rheumatoid arthritis, RA, Multiple sclerosis, MS, Lupus, Inflammatory bowel disease, IBD, Oncology, AML, Lymphoma, Immuno-oncology, Cancer immunotherapy.</p> <p data-bbox="381 489 502 510">Description:</p> <p data-bbox="381 515 689 630">Drug discovery and development company, with a focus on targeted small molecule therapeutics for cancer and autoimmune diseases.</p>	<p data-bbox="711 272 1031 389">TYK2/JAK1 inhibitor SDC-1801 targeting psoriasis, rheumatoid arthritis, inflammatory bowel disease, lupus and other autoimmune diseases (preclinical).</p> <p data-bbox="711 416 997 533">TYK2/JAK1 inhibitor SDC-1802 targeting T-ALL, ALCL, B-cell lymphoma, solid tumours and cancer immunotherapy (preclinical).</p> <p data-bbox="711 560 992 630">Aurora+FLT3 kinases inhibitor targeting AML and ALL (preclinical).</p>

Cancer: Immune Oncology


Name	About	Assets
 <p>www.adaptimmune.com</p>	<p>Keywords: T-cell therapy, Immune system, TCR therapies, Cancer, Oncology, Drug discovery and development.</p> <p>Description: Adaptimmune designs and delivers cell therapies for people with cancer, with three products in clinical trials across various solid tumor indications, and a deep pre-clinical pipeline. The Company has reported durable responses in synovial sarcoma, and initial responses in head and neck, lung, esophagogastric junction, and melanoma cancers, with its Specific Peptide Enhanced Affinity Receptor or SPEAR T-cells targeting MAGE-A4.</p>	<p>Afamitresgene autoleucel (afami-cel; previously known as ADP-A2M4)</p> <ol style="list-style-type: none"> 1) SPEARHEAD-1 Ph 2 trial in synovial sarcoma and MRCLS 2) SPEARHEAD-2 trial (combination of afami-cel and pembrolizumab) in head-and-neck cancer <p>Next- generation SPEAR T-cells targeting MAGE-A4</p> <ol style="list-style-type: none"> 1) SURPASS Ph 1 trial in bladder ovarian, non-small cell lung cancer, esophageal, gastric, esophagogastric & head & neck cancers. 2) SURPASS-2 Ph 2 trial in esophageal and esophagogastric cancers (to initiate in 2022) <p>ADP-A2AFP ADP-A2AFP Ph 1 trial in liver cancer or hepatocellular carcinoma.</p>



 <p>www.biosceptre.com</p>	<p>Keywords: Basal cell carcinoma nfP2X7 monoclonal (domain) antibody, Peptide vaccine colorectal, Breast, Prostate, Lung, Cancer, Solid tumor, Oncology, Cancer, Immuno-oncology.</p> <p>Description: Biosceptre is a UK based biotech with three products in the clinical pipeline, all targeting a novel oncology target - nfP2X7, a form of P2X7 that is expressed only in the tumor microenvironment, and which occurs in a broad range of cancers.</p>	<p>BIL03s is our systemic monoclonal (domain) antibody - for solid tumors.</p> <p>BIL06v is our peptide vaccine for solid tumors entering Phase 1 in Q2 2018.</p> <p>BIL010t is our topical Antibody treatment for locally advanced Basal Cell Carcinoma (laBCC) - Phase 2 in Q4 2018.</p>
--	--	--

Name	About	Assets
 <p>www.f-star.com</p>	<p>Keywords: Bispecific antibodies, Immunooncology, Modular Antibody technology™, Fcab™, mAb2™.</p> <p>Description: Biopharmaceutical company developing immuno-oncology bispecific antibody therapeutics, selected for their potential to transform the treatment of cancer.</p>	<p>Pipeline of disruptive immuno-oncology bispecific antibodies which outperform current combination approaches.</p> <p>Modular Antibody Technology: Highly versatile platform to efficiently develop and manufacture first-in-class drug candidates in multiple therapy areas.</p>
 <p>www.fusionantibodies.com</p>	<p>Keywords: Biotherapeutics, Drug discovery, Antibody discovery, Antibody humanisation, Affinity maturation, Bispecific development, Multi-specific, Collaborative partner.</p> <p>Description: World-leading antibody discovery and development partner. Bespoke antibody discovery platforms, multispecific format optimisation, affinity maturation & developability. (RAMP™), humanisation (CDRx™), human antibody mammalian expressed library (OptiMAL™) and Cell Line Development.</p>	
<p>IMMUNOCORE</p> <p>www.immunocore.com</p>	<p>Keywords: ImmTAC molecule, T cell receptor, Immuno-oncology, Immunology, Immunotherapy, Oncology, HLA targets metastatic uveal melanoma, Ocular melanoma, Cutaneous melanoma, Bi-specific biologic.</p> <p>Description: A leading T Cell Receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.</p>	<p>IMCgp100 in pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.</p> <p>IMCnyeso (in collaboration with GSK), ongoing Phase I clinical trial for treatment of melanoma, synovial sarcoma, urothelial carcinoma and non-small cell lung cancer (NSCLC).</p> <p>Additional undisclosed pre-clinical assets.</p>



Name	About	Assets
 The Institute of Cancer Research www.icr.ac.uk	<p>Keywords: Precision medicine, Predictive medicine, Biomarkers, Drug discovery, First-in-human clinical trials, Immuno-oncology, Big data and AI, Antibody-based therapeutics, Pre-clinical tools for testing novel agents, Radiation-combinations, Microscopy, Genomic sequencing, Drug resistance mechanisms, Imaging, Medical physics.</p> <p>Description: The Institute of Cancer Research, London, is a member college of the University of London and one of the world's leading higher education institutions in measures of collaboration and partnership with industry. It is top-ranked for research quality and impact amongst UK universities in the UK Government's definitive measure of research quality and impact - for example, having discovered 20 new drug candidates since 2005 of which 11 have reached clinical trials - and is currently working in collaboration with more than 100 companies to translate its research into new cancer treatments and technologies.</p>	

Name	About	Assets
 <p>www.karustherapeutics.com</p>	<p>Keywords: Cancer, Targeted therapy, Cancer immunotherapy, Tumour microenvironment, TME, Small molecule, Treg cell, MDSC, Immunomodulator, Immune checkpoint, B-cell lymphoma, PI3K, PI3 Kinase, HDAC6, p110b, p110d, Solid tumour, Epithelial tumour, PD-L1.</p> <p>Description: Clinic stage biopharma company developing oral small molecules for the treatment of solid tumours and haematological cancer. These molecules are in clinical trials at the MD Anderson Cancer Centre in Houston, Texas.</p>	<p>KA2237 is a first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat haematological and solid tumours, including aggressive δ/δ expressing Non-Hodgkin Lymphomas such as Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma, as well as ibrutinib resistant blood cancers.</p> <p>KA2507 is a highly-selective, oral, small molecule HDAC6 inhibitor that has potential in the treatment of liquid tumours such as multiple myeloma and lymphoma, and PD-L1-expressing tumours such as melanoma by acting as a cancer immunotherapeutic.</p>
 <p>www.kymab.com</p>	<p>Keywords: Monoclonal antibodies, Bispecific, Immunotoxins.</p> <p>Description: Clinical-stage company focusing on the discovery and development of antibodybased therapeutics in immuno-oncology, immunology, haematology and infectious diseases.</p>	<p>KY1005, anti-OX40L for autoimmune diseases (Phase I)</p> <p>KY1044, anti-ICOS for immuno-oncology</p> <p>KY1043, anti-PD-L1 immunotoxin for immuno-oncology</p> <p>KY1070, anti-BMP6 for anemia of chronic disease</p> <p>Numerous other pre-clinical assets including immuno-oncology bispecific Kymouse and IntelliSelect antibody development candidate discovery platforms.</p>
 <p>www.phiontx.co.uk</p>	<p>Description: Therapeutic vaccine development company, utilising its patented peptide based drug delivery system (DDS) termed RALA that, when combined with mRNA, generates a uniquely potent therapeutic CD8+ response, without provoking an innate immune response.</p>	<p>PTX_V1 RALA/E6-E7 mRNA Therapeutic Vaccine for Muscosal HPV.</p>

Name	About	Assets
 <p>PsiOxus THERAPEUTICS</p> <p>www.psioxus.com</p>	<p>Keywords: Immuno-oncology, Cancer, Checkpoint, Antibody, Bispecific, Oncolytic, Virus, T-cell, Gene therapy, Cytokine, delivery, CD40, aCD3, Anti-FAP, Interferon.</p> <p>Description: Clinical stage Oxford and Philadelphia based company focused on oncolytic viruses and cancer specific gene-therapy.</p>	<p>Enadenotucirev: an IV delivered oncolytic virus. In clinical studies combined with both checkpoint inhibitors and chemotherapeutic agents.</p> <p>NG-350: a cancer gene therapy directing tumor cells to secrete a CD40-agonist mAb. Entering clinical studies in Q1 2019.</p> <p>NG-641: a cancer gene therapy directing tumor cells to secrete bi-specific T-cell activators, chemokines and cytokines. Targeted at stroma dense tumors. Entering clinical studies in Q1 2019.</p>
<p>Redx Pharma</p> <p>www.redxpharma.com</p>	<p>Keywords: Non-alcoholic steatohepatitis (NASH), Small molecules, Oncology, Immune-oncology, Tumors, Cancer inhibitors, Fibrosis, IPF, Kidney fibrosis, Diabetic nephropathy.</p> <p>Description: Engaged in the discovery and development of novel small molecule therapeutics targeting high unmet needs in oncology, fibrotic and autoimmune diseases.</p>	<p>RXC004 (porcupine antagonist) - Clinical phase 1 for use in immuno-oncology combinations.</p> <p>GI-targeted ROCK inhibitor: Crohn's Disease-related fibrosis.</p> <p>Selective ROCK2 inhibitors: Non-alcoholic steatohepatitis (NASH).</p> <p>Porcupine antagonist (REDX06109): Idiopathic pulmonary fibrosis (IPF).</p> <p>Preclinical programmes to generate novel development compounds.</p>


Name	About	Assets
 <p>www.therakind.com</p>	<p>Keywords: Paediatric, Orphan, Geriatric, Drug delivery, Cytotoxic, Oral liquid, Oncology, Chemotherapy, Immunology, Reformulation.</p> <p>Description: Specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Therakind has successfully brought three products to approval in the EU/UK. An extensive pipeline of products is under development.</p>	<p>Therakind has well established expertise in developing novel oral solutions of oncology medicines having successfully launched Jylamvo® (oral solution of methotrexate). Therakind is currently developing an oral liquid oncology drug.</p>
 <p>www.vasgen.co.uk</p>	<p>Keywords: ADAMs, ADAM15, Metzincin, AMD, Cancer, AbIMP, Metalloprotease, Anti- angiogenesis.</p> <p>Description: First-in-class monoclonal antibody targeting ADAM15 for anti-angiogenesis/anti-tumor therapy in aggressive prostate cancer & other solid tumors: lead identification.</p>	<p>First-in-class monoclonal antibody therapy for neovascular age-related macular degeneration: pre-clinical.</p> <p>AbIMP® platform: Target- enabling antibody platform for selective inhibition of intractable metzincin proteases: proof-of- concept.</p>

Cardiovascular, Respiratory and Metabolic Disease

Name	About	Assets
 <p>www.lifearc.org</p>	<p>Keywords: Heart attack (MI), Tuberculosis (TB), Diagnostic antibodies, Protein, Peptide, Pulmonary fibrosis, Type-2 immune response, Humanized antibody, Inflammatory response.</p> <p>Description: LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.</p>	<p>Cardiovascular</p> <p>Myocardial Infarction; small molecule for cardioprotection following ischemia-reperfusion injury during heart attack.</p> <p>Respiratory</p> <p>IL17BR humanized antibody.</p>
 <p>www.innovation.ox.ac.uk</p>	<p>Keywords: miR-31, Atrial fibrillation, nNOS.</p> <p>Description: Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.</p> <p>More information on our technologies can be found at: https://innovation.ox.ac.uk/technologies-available</p>	<p>miR-31 as a specific target for regulating atrial fibrillation.</p>



Name	About	Assets
 <p>www.therakind.com</p>	<p>Keywords: Drug delivery, Severe hypoglycemia, Diabetes, Intranasal device, Reformulation.</p> <p>Description: Specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Therakind has successfully brought three products to approval in the EU/UK. An extensive pipeline of products is under development.</p>	<p>Undisclosed nasal powder for severe hypoglycemia.</p> <p>Partnership/funding opportunities available.</p>
 <p>www.vectura.com</p>	<p>Keywords: Airways disease, Respiratory, formulation, Inhalation, Asthma, COPD, Inflammatory, PAH, Cystic fibrosis, RSV.</p> <p>Description: Develops inhalation products for respiratory diseases. 7 inhaled, 4 non-inhaled and 10 oral products marketed by partners. Out-license agreements for a portfolio of drugs in clinical development.</p>	<ul style="list-style-type: none"> • DPI device technologies GyroHaler®, Lever-operated, Open-inhale-close, Unit-dose • pMDI device technologies flutiform® • Smart nebuliser delivery systemsnAKITA® JET, FOX® • Formulation technologies • A range of formulation technologies for inhaled small and large molecules for pMDI and DPI dosage forms.
 <p>www.yaqrit.com</p>	<p>Keywords: Liver disease, Cirrhosis, ACLF, NASH, NAFLD, ALF, Alcoholic cirrhosis.</p> <p>Description: Yaqrit is developing treatments for liver disease. Twenty years of work in liver disease has led to a family of breakthroughs, now combined with experienced management to bring new treatments to liver patients around the world.</p>	<p>Yaqrit had two programs entering Phase II clinical trials in 2017. Two of them are supported by EU Horizon 2020 grants worth a total of €12.3M.</p>


Drug Delivery


Name	About	Assets
 <p data-bbox="73 392 250 416">www.apconix.com</p>	<p data-bbox="381 272 488 293">Keywords:</p> <p data-bbox="381 296 687 464">Ion channel screening, Target safety assessments, Drug project toxicology, Due diligence, toxicology specialists, Study monitoring, hERG, CiPA, Nonclinical, Pre clinical, Drug discovery, Drug development.</p> <p data-bbox="381 488 502 509">Description:</p> <p data-bbox="381 512 701 874">Apconix is a team of world-renowned drug safety experts providing support and guidance in all aspects of pharmaceutical safety strategy and execution. Services include toxicology program design and delivery, target safety assessments and ion channel biology. With over 400 years of industry experience, our focus is on providing high quality, fit-for-purpose, cost-effective toxicology support that perfectly align with clinical and regulatory objectives.</p> <p data-bbox="381 898 695 1018">Apconix is based at Alderley Park and this is where our ion channel laboratory is located. We have colleagues across the UK, Europe and North America.</p>	<p data-bbox="712 272 945 341">QPatch II and PatchLiner automated patchclamp instruments.</p> <p data-bbox="712 368 1042 560">Expert toxicologists in genetic, general, reproductive and juvenile toxicology, safety and secondary pharmacology, DMPK, pathology, immunotoxicology, CRO selection and study monitoring, impurity qualification, OEL and PDE calculation.</p> <p data-bbox="712 584 956 655">During 2020, Apconix supported our clients with 9 IND applications/CTAs.</p>

Name	About	Assets
 <p>CrystecPharma <i>performance in every particle®</i></p> <p>www.crystecpharma.com</p>	<p>Keywords: Small molecules, Large molecules, Inhaled and nasal delivery, Dissolution and bioavailability enhancement, Improved stability, Particle engineering, Crystallisation.</p> <p>Description: Crystec applies an innovative supercritical fluid (SCF) crystal and particle technology to optimise product performance and support the development of strongly differentiated therapeutics in a range of dosage forms.</p>	<p>mSAS® (modified Supercritical Anti-Solvent) SCF technology:</p> <ul style="list-style-type: none"> • Dissolution enhancement • Inhaled therapies • Simplified formulations • Stabilised biomolecules • Enhanced polymorph screening • Rapid product development
 <p>Enesi Pharma</p> <p>www.enesipharma.com</p>	<p>Keywords: ImplaVax™, Vaccines, Injectable solid-dose, Drug-device combinations, Needle-free, Enhanced immunogenicity, No cold chain.</p> <p>Description: Clinical-stage company developing in tivo drug device combination products with potential to transform performance and delivery of vaccines and therapeutics and make a material impact of global healthcare.</p>	<p>ImplaVax™ integrated proprietary solid dose formulation and device technology. Enhances immune response and immunogenicity. Dose and regimen sparing demonstrated. Needle free, syringe free, adjuvant free Eliminates need for point-of care reconstitution with diluent.</p> <p>Eliminates needle-stick-injury and sharps disposal challenge. Unit dose delivery assured - each time, every time. Enhanced stability with reduced/ eliminated cold chain.</p>
 <p>LifeArc</p> <p>www.lifearc.org</p>	<p>Keywords: Cell-penetrating, Peptide, Therapeutic, Delivery.</p> <p>Description: LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.</p>	<p>Cell penetrating peptides with demonstrated efficacy in transporting biological molecules into cells and improving disease outcome in vivo.</p>


Name	About	Assets
 <p>www.midatechpharma.com</p>	<p>Keywords: Sustained delivery, Long-Acting Injectable, Local delivery, Microsphere encapsulation.</p> <p>Description: Midatech Pharma PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines and developing a pipeline of differentiated products for sustained release and targeted delivery.</p>	
 <p>www.nanomerics.com</p>	<p>Keywords: Acute/chronic neuropathic pain, Ocular therapy, Ophthalmology, Fungal infections, Leishmaniasis.</p> <p>Description: Nanomerics' award winning Molecular Envelope Technology (MET) delivers a step change in target-site availability of hydrophobic drugs and peptide APIs across epithelial barriers.</p>	<p>Oral: e.g. switch from intravenous, e.g. NM-0147 an oral form of Amphotericin B.</p> <p>CNS: direct delivery via nose-to-brain, e.g. NM-0127 a strong opioid replacement analgesic.</p> <p>Ocular: front and back of the eye, e.g. NM133 once daily aqueous non- burning treatment for dry eye (North American rights licensed, other rights available).</p>
 <p>www.phiontx.co.uk</p>	<p>Description: Therapeutic vaccine development company, utilising its patented peptide based drug delivery system (DDS) termed RALA that, when combined with mRNA, generates a uniquely potent therapeutic CD8+ response, without provoking an innate immune response.</p>	<p>PTX_V1 RALA/E6-E7 mRNA Therapeutic Vaccine for Muscosal HPV.</p>


Name	About	Assets
 <p data-bbox="76 395 303 419">www.quaypharma.com</p>	<p data-bbox="381 272 501 293">Description:</p> <p data-bbox="381 296 678 485">Quay are world renowned for our formulation development and clinical manufacturing, and our understanding of poor soluble and bioavailable small molecules, plus our formulation development and clinical services include:</p>	<ul data-bbox="736 272 1023 671" style="list-style-type: none"> • Immediate release and controlled release tablets. • Multilayer tablets. • Immediate release capsules. • Oral multi particulates such as beads, pellets and mini-tablets. • Liquid and semi-solid filled capsules. • Fast dispersible tablets. • Coating of tablets, capsules and pellets. • Micro-encapsulation using spray drying. • Oral liquids and suspensions.
 <p data-bbox="76 823 269 847">www.therakind.com</p>	<p data-bbox="381 716 486 737">Keywords:</p> <p data-bbox="381 740 678 788">Drug delivery, Intranasal device, Reformulation.</p> <p data-bbox="381 812 501 833">Description:</p> <p data-bbox="381 836 684 1075">Specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Therakind has successfully brought three products to approval in the EU/UK. An extensive pipeline of products is under development.</p>	<p data-bbox="712 711 1037 1075">DriDose® - a novel passive nasal dry powder delivery device (patent granted US, EU, Canada, Japan and China). The proof of concept of this device has been successfully demonstrated in clinical trial using a dry powder nasal formulation of a diabetic drug for the treatment of severe hypoglycaemic reactions. This is a platform delivery device applicable to multiple drugs in different therapeutic areas (vaccine, peptide and hormone delivery). Seeking collaborative partners to utilise platform.</p>


Name	About	Assets
 www2.warwick.ac.uk/services/ventures/	<p>Keywords: Technology transfer, Anti-infectives, Antivirals, Women's health, Oncology, Cancer, Drug discovery platforms, Biologics delivery platform, Diabetes, Cryopreservation.</p> <p>Description: The University of Warwick's (UK), Technology Development and Commercialisation Office.</p>	<p>Protein-based nanoscale injection platform for the cell-specific delivery of biologics.</p> <p>Other opportunities can be found here:</p> <p>http://www2.warwick.ac.uk/services/ventures/licensing/licensing-opportunities/</p>

 www.xeneticbio.com	<p>Keywords: Biologics, Anemia, Pre-dialysis, CKD, Erythropoietin, EPO, Polysialic acid, Polysialylation, PSA, PSA-EPO, PolyXen™.</p> <p>Description: Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics.</p>	<p>Polysialylated EPO, in Phase II for anemia in pre-dialysis CKD patients.</p> <p>PolyXen™, a patented platform technology for creating proprietary, next-generation protein and peptide therapeutics.</p>
--	---	---

Genetics, Genomics and Gene Therapy

Name	About	Assets
 <p data-bbox="75 403 280 427">www.congenica.com</p>	<p data-bbox="384 272 488 296">Keywords:</p> <p data-bbox="384 300 673 488">Clinical genomics, Rare disease diagnosis, Genome interpretation, Next generation sequencing, NGS, WES, WGS, Genomic software, Genome analysis, Exome analysis, Genetic variant interpretation software.</p> <p data-bbox="384 515 505 539">Description:</p> <p data-bbox="384 542 684 707">Congenica is a global company founded on pioneering research from the Wellcome Trust Sanger Institute. We've translated this research into the gold standard clinical genomics analytics platform, Sapiaientia.</p>	<p data-bbox="714 272 1022 464">Congenica has developed Sapiaientia, a platform that integrates a suite of analytical tools enabling rapid and accurate interpretation of a patient's genotype and phenotype data to facilitate a faster and more accurate diagnosis.</p>

Name	About	Assets
 www.kinomica.com	<p>Keywords: Proteomics, Phosphoproteomics, Kinases, Preclinical, Clinical, Personalised medicine, Diagnostics, Oncology, Biomarkers, Mass spectrometry, Bioinformatics, LCMSMS, Mode of action, Target discovery, Patient stratification, Drug discovery, Drug development, Kinase inhibitors.</p> <p>Description: Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. We offer KScan™, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage.</p> <p>We offer KScan™ for: (1) improved monitoring of drug molecular efficacy and response (to fully elucidate mode of action and mechanisms of resistance); and (2) discovery of predictive biomarkers for patient selection and stratification in clinical trials. We also offer additional advanced proteomics services, including the assessment of molecular target turnover and target engagement. Kinomica's approach to measuring the phosphorylation signature of proteins, rather than using gene expression, provides a direct snapshot of protein and cell-signalling activity. We have preclinical proof-of-concept data to demonstrate that our game-changing biomarkers predict drug response more accurately than current state-of-the-art gene sequencing.</p>	

Name	About	Assets
 <p>www.liptide.com</p>	<p>Keywords: Gene therapy, siRNA, Gene editing, DNA, RNA vaccine, Delivery, Viral, LipTide, Liposome, Crispr, CAS9, saRNA, mRNA, DNA, Plasmid.</p> <p>Description: Nanogenics is proud to introduce LipTide™; an exciting custom-built delivery vehicle for all gene therapy. Every aspect of LipTide™ can be modified to target different cell types and deliver different payloads. Nanogenics are looking to out-licence LipTide™ to help translate your gene therapy into potential clinical programs.</p>	<p>LipTide™ can be modified to target different cell types and does not accumulate in the liver.</p> <p>LipTide™ has been successfully administered in vivo by nebulization, systemic delivery (i.v.) and by convection-enhanced delivery to the brain.</p> <p>LipTide™ delivers for all nucleic acid payloads including siRNA, saRNA, mRNA, DNA and even artificial chromosomes.</p>



Keywords:
Gene therapy, Cell therapy, Lentiviral vectors, Adenoviral vectors, Ocular, CNS, Oncology, CAR-T, COVID-19 vaccine, Bioprocessing/manufacturing.

Description:
The Company's LentiVector® platform is the first commercially approved lentiviral based gene delivery system.

Oxford Biomedica is involved at all stages of development for both proprietary and partners' lentiviral vector based products, and also manufactures the adenovirus based AstraZeneca COVID-19 vaccine.

Oxford Biomedica has world class GMP facilities for viral vector production.

Integrated LentiVector® platform for gene delivery.

OXB-203
Wet AMD (ocular)
Pre-clinical.


OXB-204
LCA-10 (ocular)
Pre-clinical.

OXB-302
CART-5T4 (cancer)
Pre-clinical.

OXB-103 ALS (CNS)
Pre-clinical.

OXB-401 Liver indication
Pre-clinical.

Name	About	Assets
 <p>www.phiontx.co.uk</p>	<p>Description: Therapeutic vaccine development company, utilising its patented peptide based drug delivery system (DDS) termed RALA that, when combined with mRNA, generates a uniquely potent therapeutic CD8+ response, without provoking an innate immune response.</p>	<p>PTX_V1 RALA/E6-E7 mRNA Therapeutic Vaccine for Mucosal HPV.</p>
 <p>www.silence-therapeutics.com</p>	<p>Keywords: Genetic medicine, Pancreatic cancer, hHead and neck cancer, Lung disease, Pulmonary hypertension, RNA interference, Gene silencing, Messenger RNA, RNAi, mRNA.</p> <p>Description: Clinical-stage company which utilizes RNA interference (RNAi) and mRNA technology to develop therapies which 'silence' disease-causing gene expression.</p>	<p>Atu027, against pancreatic cancer, Phase II.</p> <p>Atu027, against head and neck cancer, Phase I.</p> <p>Atu111, against lung indications, pre-clinical.</p> <p>Unnamed, against pulmonary hypertension, discovery-stage.</p> <p>Pre-clinical micro RNA and messenger RNA programs.</p>
 <p>TOUCLIGHT</p> <p>www.touchlight.com</p>	<p>Keywords: DNA, Non-viral gene therapy, Cell therapy, mRNA, Monoclonal antibodies, Cancer vaccine, Prophylactic vaccine, DNA vaccine; AAV, Lentivirus.</p> <p>Description: Touchlight has developed "dbDNA", a minimal, linear, covalently closed DNA molecule with unique characteristics and broad applicability across advanced therapeutics. dbDNA is produced by a rapid, scalable enzymatic process.</p>	<p>Touchlight has a Contract Development and Manufacturing offering that produces GMP dbDNA vectors for genetic medicines products. Touchlight is also developing prophylactic and therapeutic DNA vaccines in-house.</p>

Name	About	Assets
 <p>Connected Innovation</p> <p>www.valirx.com</p>	<p>Keywords: Oncology, Prostate cancer, Breast cancer, Ovarian cancer, Endometriosis, Lung cancer, Women's health, Peptides, Small molecules.</p> <p>Description: ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.</p>	<p>VAL 201, against prostate cancer (with potential in breast and ovarian cancers, endometriosis), Phase I.</p> <p>VAL 401, against lung cancer, Phase II.</p>

Infectious Disease and Virology

Name	About	Assets
 <p>iQur www.iqur.com</p>	<p>Keywords: Vaccines, Virology, Infectious disease, Virus-like particles, Influenza, Malaria, Hepatitis, Burkholderia, FMDV, CMV, Cancer, Tandem Core™, Diagnostics, Liver fibrosis test, Clinical stage.</p> <p>Description: Preclinical- stage company focused on the development of a broad spectrum of vaccines delivered as proprietary virus-like particles (VLPs).</p>	<p>Vaccines for:</p> <p>Influenza, pre-clinical Malaria, pre-clinical Hepatitis, pre-clinical FMDV, pre-clinical CMV, pre-clinical Cancers, discovery and development stage Influenza virus A point of care rapid diagnostic, pre-clinical.</p>
 <p>www.lifearc.org</p>	<p>Keywords: Vaccines, Diagnostics, Mouse models, New class of antivirals, HIV-1, Asthma, Ulcerative colitis (UC), Tuberculosis (TB).</p> <p>LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.</p>	<p>Tuberculosis; rapid ex vivo diagnostic.</p> <p>HIV-1; a universal HIV-1 vaccine called HIVcon.</p> <p>Asthma and Ulcerative Colitis; antibody against IL-25 and type 2 immune responses, humanized.</p> <p>Junbo, a mouse model with OM for antibiotic research.</p>
 <p>www.novabiotics.co.uk</p>	<p>Keywords: Anti-infectives, Antibacterial and antifungal therapies, MDR infections, Gram-negative bacterial infections cystic fibrosis, Onychomycosis, Aspergillosis.</p> <p>Description: NovaBiotics is a leading AMR focused, clinical- stage company developing antibacterial and antifungal therapies from its novel AMR focused technology platforms that have been engineered from components of the innate immune response to infection.</p>	<p>NovaBiotics has three advanced product candidates in clinical development (Lynovex, Novexatin, Luminaderm) for difficult to treat bacterial and fungal infections, plus;</p> <p>Earlier stage compounds for MDR bacterial Gram negative infections, MRSA, aspergillosis, candidemia, cryptococcosis.</p> <p>Therapeutic candidates have been developed from two novel AMR focused platforms based on innate immune antimicrobial peptides and cysteamine.</p>

Name	About	Assets
 <p>www.innovation.ox.ac.uk</p>	<p>Keywords: DENV proteins, Dengue vaccine, Dengue fever, DENV, Hepatitis C vaccine, HCV (10355).</p> <p>Description: Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world. More information on our technologies can be found at: https://innovation.ox.ac.uk/technologies-available</p>	<p>Dengue fever vaccine designed to generate full protection against all DENV serotypes.</p> <p>DENV vaccine using non-replicating viral-vectored vaccines to induce T-cell responses against a single immunogen incorporating the most conserved non-structural DENV proteins. This vaccine has been designed to generate full protection against all DENV serotypes. HCV vaccine using non-replicating viral-vectored vaccines to induce T-cell responses against a single immunogen incorporating the most conserved proteins of HCV, including non-structural proteins.</p>
 <p>www.phiontx.co.uk</p>	<p>Description: Therapeutic vaccine development company, utilising its patented peptide based drug delivery system (DDS) termed RALA that, when combined with mRNA, generates a uniquely potent therapeutic CD8+ response, without provoking an innate immune response.</p>	<p>PTX_V1 RALA/E6-E7 mRNA Therapeutic Vaccine for Mucosal HPV.</p>
 <p>www.reviral.co.uk</p>	<p>Keywords: Antiviral, RSV, Respiratory syncytial virus.</p> <p>Description: ReViral is a leading antiviral company progressing a best-in-class inhibitor of RSV. The Company has recently completed a Phase 1 clinical trial with excellent exposure and no significant adverse events.</p>	<p>An RSV fusion inhibitor RV521 recently completed a successful Phase 1 clinical trial.</p> <p>RSVrep, for RSV, in pre-clinical development.</p>

Name	About	Assets
 <p>www.virionbiotx.com</p>	<p>Keywords: Biological Antiviral, Broad Spectrum, Respiratory, Infectious disease, Respiratory virus infections, Influenza, RSV.</p> <p>Description: Preclinical company focused on the development of first in class Therapeutic Interfering Particles for treatment of Respiratory Virus Infections.</p>	<p>Lead product is a Therapeutic interfering Particle with a dual mechanism of action, genomic interference and stimulation of the innate immunity.</p> <p>Provides broad spectrum treatment for the full range of viruses that cause respiratory infections, addressing both influenza and the 85% of respiratory virus infections caused by other viruses.</p>
 <p>www2.warwick.ac.uk/services/ventures</p>	<p>Keywords: Technology transfer, Anti-infectives, Antivirals, Women's health, Oncology, Cancer, Drug discovery platforms, Biologics delivery platform, Diabetes, Cryopreservation.</p> <p>Description: The University of Warwick's (UK), Technology Development and Commercialisation Office.</p>	<ol style="list-style-type: none"> 1. Anti-RSV DDX3 Inhibitor. 2. Natural Product Discovery Platform producing compounds active against a range of bacterial pathogens. Including those that have shown promising and specific activity against the Gram-negative, multidrug-resistant bacterium <i>Acinetobacter baumannii</i>. 3. GLO-1 Inducer for Diabetic Kidney Disease. 4. Anti-infective (gram +ve and gram -ve) Metallohelices. 5. Anti-cancer Metallohelices. 6. Cyro-preservation compounds and methodologies for cells, blood and proteins. <p>Other opportunities can be found here: http://www2.warwick.ac.uk/services/ventures/licensing/licensing-opportunities/</p>

Central Nervous System

Name	About	Assets
 <p>www.autifonytherapeutics.com</p>	<p>Keywords: Hearing loss, Schizophrenia, Fragile X, Dementia, Alzheimer's disease.</p> <p>Description: Clinical stage company focused on therapeutics for CNS disorders, including schizophrenia, Fragile X and hearing disorders, and with an earlier stage dementia programme.</p>	<ol style="list-style-type: none"> 1. AUT00206, for schizophrenia, Phase Ib studies ongoing. 2. AUT00206 has Orphan Drug Designation for Fragile X from FDA. 3. Preclinical stage hearing programme. 4. Lead Optimisation stage dementia programme.
 <p>www.cholestenix.com</p>	<p>Keywords: Neurodegenerative disease, Cholesterol metabolites, Oxysterols, Cholestenic acids, Motor neuron disease, ALS, Parkinson's disease, Alzheimer's disease, Therapeutics, LC-MS/MS diagnostics and biomarkers.</p> <p>Description: A new drug and diagnostic development company focused on the roles of cholesterol metabolites, oxysterols and bile acids in the brain in neurodegenerative diseases.</p>	<p>CHX100 & CHX100-xD, a natural cholestenic acid and its site-specific deuterated analogue for treatment of motor neuron disease/ALS.</p> <p>Discovery therapeutic projects on the role of other cholesterol metabolites in Alzheimer's, Parkinson's and breast cancer.</p> <p>Quantitative LC-MS/MS diagnostics/biomarkers for ALS and several orphan diseases.</p>
 <p>www.chronostherapeutics.com</p>	<p>Keywords: Long COVID Fatigue and anxiety, MS, Eating disorders, Addictive behaviors.</p> <p>Description: Peri-clinical-stage company focused on the development of NCEs in degenerative and behavioral diseases of the CNS.</p>	<p>DAT Inhibitor in COVID/MS fatigue orexin-1 antagonist in COVID anxiety/addictive behaviors.</p> <p>TrkB activator in PTSD.</p>

Regenerative Medicine, Medical Devices and Software

Name	About	Assets
 <p>The Institute of Cancer Research</p> <p>www.icr.ac.uk</p>	<p>Keywords: Precision medicine, Predictive medicine, Biomarkers, Drug discovery, First-in-human clinical trials, Immuno-oncology, Big data and AI, Antibody-based therapeutics, Pre-clinical tools for testing novel agents, Radiation-combinations, Microscopy, Genomic sequencing, Drug resistance mechanisms, Imaging, Medical physics.</p> <p>Description: The Institute of Cancer Research, London, is a member college of the University of London and one of the world's leading higher education institutions in measures of collaboration and partnership with industry. It is top-ranked for research quality and impact amongst UK universities in the UK Government's definitive measure of research quality and impact - for example, having discovered 20 new drug candidates since 2005 of which 11 have reached clinical trials - and is currently working in collaboration with more than 100 companies to translate its research into new cancer treatments and technologies.</p>	<p>Device for tissue processing: prototypes sold to academic researchers.</p> <p>Endocavitary coil for improved 3T-MR diagnostic imaging of the cervix (proof of concept, clinical ongoing).</p> <p>Polyscope: solution for visualization of digital microscopic samples (pre- production prototype in development).</p> <p>ARF-LOVIT system: for reducing clutter in medical photoacoustic, ultrasound and other imaging using acoustic radiation force-based localised vibration tagging.</p> <p>3D Kinetic Volume Rendering Tool for MRI: software to enable separate display of MIPs derived from different phases of MR contrast capable kinetics.</p> <p>MRI Distortion Correction: Algorithms for evaluation and correction of geometric distortion in MR images, for applications including radiotherapy treatment planning.</p>



<p>Keywords: Tissue regeneration, orthopedic matrices, Cell therapy, Drug delivery, Injectables, Tissue scaffolds.</p> <p>Description: Preclinical-stage company focused on the development of their proprietary TAOS injectable matrix technology, and several potential applications thereof.</p>	<p>TAOS osteoinductive therapeutic for orthopedic bone and joint fusion indications, pre-clinical.</p> <p>TAOS osteoconductive void filler for grafting procedures, pre-clinical.</p> <p>RPMMax - thermoreversible 3D scaffold for trypsin-free cell expansion.</p> <p>IntraStem - high-performance intracellular update agent.</p>
---	---

Name	About	Assets
------	-------	--------

Overwatch®

www.overwatchresearch.com

Keywords:

Preclinical, Software, In vivo, Study management, Colony management, Reproducibility, ELN

<https://vimeo.com/282320163>

Description:

Overwatch is an in vivo study management platform, used by leading pharmaceutical companies and biotechs, designed to combat the reproducibility crisis that is currently plaguing the preclinical research industry.



www.innovation.ox.ac.uk

Keywords:

Deep brain stimulation, Neuroscience, Implant, Surgery, Brain surgery.

Description:

Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, providing consultancy services to clients around the world and determining position suitability for implantation of deep brain stimulation leads. More information on our technologies can be found at: <https://innovation.ox.ac.uk/technologies-available/>

A method for assessing the suitability of a target for deep brain stimulation (DBS) and for assessing the suitability of the implanted position of a DBS lead. The method uses electrophysiological signals obtained from multiple electrodes to determine the proximity of an implanted DBS lead to a target implantation position. This avoids the risk of adverse side effects caused by incorrect position and is less prone to error than current methods.

Multiple Therapeutic Areas


Name	About	Assets
 <p>www.abcodia.com</p>	<p>Keywords: Biomarkers, Validation, Human serum, Cancer, Cardiovascular disease, Diabetes, Population studies.</p> <p>Description: Abcodia licenses access to a unique longitudinal serum bio bank that allows biomarkers to be studied within individuals and across a population over time, from healthy to diagnosis and therapy.</p>	<p>Serum bio bank derived from 202,000 initially free from cancer postmenopausal women, 50,000 of whom donated annually for 10 years.</p> <p>The bank is available for biomarker discovery and validation work and covers every disease such a large population would develop in 15 years.</p>
 <p>www.biogelx.com</p>	<p>Keywords: 3D cell culture, Peptide hydrogels, Organoids, Tissue culture, Cancer research, Toxicology assays, 3D bio-printing, Regenerative medicine, Drug delivery.</p> <p>Description: Hydrogels for culturing cells on a realistic environment that mimics the human body. Research product for cell biology applications and 3D bioprinting.</p>	<p>Biogelx technology is revolutionizing the way cell biologists control cell behavior in the laboratory. The gels can be tuned to mimic specifically the environment in which the cells grow in vivo, allowing them to thrive.</p> <p>Biogelx materials are a family of hydrogel products with tunable mechanical properties, optimized for 3D cell culture, bioprinting and drug delivery. Biogelx functionalized gel powders offer additional chemical tunability, integrating biomimetic peptide sequences for additional functionality.</p>
 <p>www.crystecpharma.com</p>	<p>Keywords: Urology, Genitourinary, Women's health, Respiratory, Urge incontinence, Anticholinergic, Inhaled, Particle engineering, Fast onset.</p> <p>Description: Crystec applies mSAS®, a supercritical fluid based crystal and particle technology to enable the development of innovative medicines in a range of therapeutic areas including urology, respiratory, women's health and infectious disease.</p>	<p>CR002: The first on-demand treatment for urge urinary incontinence.</p> <p>CR003: An innovative therapy in women's health.</p> <p>CR601: A fast-acting treatment for intractable migraine.</p> <p>CR402: COPD combination therapy.</p>


Name	About	Assets
 <p data-bbox="73 363 275 384">www.exploristics.com</p>	<p data-bbox="381 272 687 560">Keywords: Biosimulation, Biostatistics services, Biostatistics consultancy, Clinical development, Clinical program optimization, Clinical trial design, Data analytics, KerusCloud software, Real-world data, Real-world data analytics, Statistical software, Simulation software, Synthetic data, Synthetic data generation.</p> <p data-bbox="381 587 687 826">Description: Exploristics is a global provider of biosimulation software and biostatistics services for designing, analysing and reporting clinical trials and real-world studies. We transform clinical development with our study design platform, KerusCloud.</p>	<p data-bbox="712 272 966 344">KerusCloud software Statistical analysis and reporting algorithm library.</p>
 <p data-bbox="73 983 227 1003">www.fora.health</p>	<p data-bbox="381 874 656 1090">Keywords: Remote patient monitoring, Digital health, ePROs, Cognition, ISO 13485, Patient engagement, Shared decision-making, Real-world data, Configurable platform, Disease management, Major depressive disorder.</p> <p data-bbox="381 1114 641 1329">Description: A configurable platform engaging patients to gather and share information from their own mobile devices - supporting remote clinical research and better healthcare conversations in different therapeutic areas.</p>	<p data-bbox="712 874 992 1038">Fora Health is a platform that links a patient-facing smartphone app with a clinical team web app - powering remote patient monitoring in clinical research and healthcare.</p> <p data-bbox="712 1066 992 1185">A user-friendly conversational interface fosters patient activation and shares data to EMR-integrated clinical web interfaces.</p> <p data-bbox="712 1212 992 1377">Data collection and management is configured to the needs of clinical teams, from validated ePROs and cognitive assessments, to tracking goals, medication adherence and side effects.</p>

Name	About	Assets
 <p data-bbox="76 432 208 448">fusionantibodies</p> <p data-bbox="76 472 340 493">www.fusionantibodies.com</p>	<p data-bbox="381 272 486 293">Keywords:</p> <p data-bbox="381 298 664 440">Biotherapeutics, Drug discovery, Antibody discovery, Antibody humanisation, Affinity maturation, Bispecific development, Multi-specific, Collaborative partner.</p> <p data-bbox="381 467 501 488">Description:</p> <p data-bbox="381 493 639 778">World-leading antibody discovery and development partner. Bespoke antibody discovery platforms, multispecific format optimisation, affinity maturation & developability, (RAMP™), humanisation (CDRx™), human antibody mammalian expressed library (OptiMAL™) and Cell Line Development.</p>	
<p data-bbox="76 826 277 887">hikma.</p> <p data-bbox="76 906 236 927">www.hikma.com</p>	<p data-bbox="381 826 486 847">Keywords:</p> <p data-bbox="381 852 661 967">Generic, Injectable, Antiinfectives, Cardiovascular, Central nervous system, Diabetes, Oncology, Pain management and respiratory.</p> <p data-bbox="381 979 507 1000">Description:</p> <p data-bbox="381 1005 647 1099">Supplies a broad range of generic injectable medicines to treat diseases across therapeutic categories.</p>	<p data-bbox="711 826 1003 895">Currently developing a growing www.hikma.com pipeline of new products.</p>
 <p data-bbox="76 1297 340 1318">www.hyphadiscovery.co.uk</p>	<p data-bbox="381 1145 486 1166">Keywords:</p> <p data-bbox="381 1171 650 1313">Natural products, Screening library metabolite production, Glucuronide synthesis, Lead diversification, CH-activation, Late-stage functionalization.</p> <p data-bbox="381 1326 507 1347">Description:</p> <p data-bbox="381 1351 673 1513">Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites.</p>	<p data-bbox="711 1145 1014 1214">Entomopathogenic fungi derived fraction library available for screening.</p> <p data-bbox="711 1243 1022 1409">An efficient platform to produce up to gram amounts of hard to synthesise metabolites and late stage functionalized derivatives of lead compounds for SAR studies and identification of active metabolites.</p> <p data-bbox="711 1437 966 1506">The platform also allows collaborative diversification of failed clinical assets.</p>


Name	About	Assets
<p>ILLINGWORTH RESEARCH GROUP a SYNEOS HEALTH company</p> <p>www.illingworthresearch.com</p>	<p>Keywords: Mobile and on-site research nursing, Patient concierge, Patient app, Patient centricity, Medical photography, Respiratory, Orphan diseases, Dermatology.</p> <p>Description: Illingworth Research Group, a Syneos Health® company, provides a range of patient-focused clinical research home health services to the biopharmaceutical and medical device industries globally. This includes mobile research nursing, patient concierge, medical photography and clinical research services across all study phases and a diverse range of therapeutic areas.</p>	


Name	About	Assets
<p>ICR The Institute of Cancer Research</p> <p>www.icr.ac.uk</p>	<p>Keywords: Precision medicine, Predictive medicine, Biomarkers, Drug discovery, First-in-human clinical trials, Immuno-oncology, Big data and AI, Antibody-based therapeutics, Pre-clinical tools for testing novel agents, Radiation-combinations, Microscopy, Genomic sequencing, Drug resistance mechanisms, Imaging, Medical physics.</p> <p>Description: The Institute of Cancer Research, London, is a member college of the University of London and one of the world's leading higher education institutions in measures of collaboration and partnership with industry. It is top-ranked for research quality and impact amongst UK universities in the UK Government's definitive measure of research quality and impact - for example, having discovered 20 new drug candidates since 2005 of which 11 have reached clinical trials - and is currently working in collaboration with more than 100 companies to translate its research into new cancer treatments and technologies.</p>	<p>Biomarker for DNA damaging therapy; CHD1 deletion sensitises prostatic epithelial cells to DNA damaging treatments such as carboplatin and PARP inhibitors.</p> <p>Biomarker for CDK4/6 inhibitors; Loss of CREB binding protein and sensitivity to CDK4/6 inhibitors.</p> <p>Patient stratification for PARP Inhibitors: SF3B1 deficient cancers for treatment with PARP inhibitors.</p>

Name	About	Assets
 www.kinomica.com	<p>Keywords: Proteomics, Phosphoproteomics, Kinases, Preclinical, Clinical, Personalised medicine, Diagnostics, Oncology, Biomarkers, Mass spectrometry, Bioinformatics, LCMSMS, Mode of action, Target discovery, Patient stratification, Drug discovery, Drug development, Kinase inhibitors.</p> <p>Description: Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. We offer KScan™, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage.</p> <p>We offer KScan™ for: (1) improved monitoring of drug molecular efficacy and response (to fully elucidate mode of action and mechanisms of resistance); and (2) discovery of predictive biomarkers for patient selection and stratification in clinical trials. We also offer additional advanced proteomics services, including the assessment of molecular target turnover and target engagement. Kinomica's approach to measuring the phosphorylation signature of proteins, rather than using gene expression, provides a direct snapshot of protein and cell-signalling activity. We have preclinical proof-of-concept data to demonstrate that our game-changing biomarkers predict drug response more accurately than current state-of-the-art gene sequencing.</p>	

Name	About	Assets
 <p>www.lifearc.org</p>	<p>Keywords: Medical devices, Advanced wound healing, Regenerative medicine, Product packaging, Imaging, TEM, OPT, HTS, Graphene delivery.</p> <p>Description: LifeArc, the new name for Medical Research Council Technology (MRC Technology, MRCT) is a British life science medical research charity. It was established in 2000 to translate the work of UK Medical Research Council research scientists.</p>	<p>Optical projection tomography (OPT) 3D microscopy.</p> <p>Novel graphene support films for biological molecules.</p> <p>Flywheel, a platform for live HTS imaging. GMCSH-PGE, for wound healing, topical or in dressings.</p> <p>Oxygen sensors for packaging (shelf-life monitor).</p>

 <p>National Institute for Health Research</p> <p>www.nihr.ac.uk</p>	<p>Keywords: Clinical Research, Experimental medicine, Patients, Biobanks, Samples, Patient data, Research delivery, Funding, Translational research, Collaboration.</p> <p>Description: Through its people, funding programmes, centres of excellence and systems, spanning across the UK's health system and leading universities, the NIHR is designed to transform scientific breakthroughs into life-saving treatments and technologies.</p> <p>As a leading destination for clinical research, the NIHR can support life science companies generate the required clinical and economic evidence to progress the development of their new therapeutics, MedTech, diagnostics and digital products towards the market.</p>	<p>Biomedical Research Centres</p> <p>MedTech and In Vitro Diagnostic Cooperatives</p> <p>Translational Research Collaborations</p> <p>UK Clinical Research Facility Network</p> <p>BioResource</p> <p>Applied Research Collaborations</p> <p>NIHR Funding Programmes</p> <p>Clinical Research Network</p> <p>Patient Recruitment Centres</p>
--	--	---


Name	About	Assets
<p>Overwatch®</p> <p>www.overwatchresearch.com</p>	<p>Keywords: Preclinical, Software, In vivo, Study management, Colony management, Reproducibility, ELN.</p> <p>Description: Overwatch is an in vivo study management platform, used by leading pharmaceutical companies and biotechs, designed to combat the reproducibility crisis that is currently plaguing the preclinical research industry.</p>	<p>https://vimeo.com/282320163</p>
<p></p> <p>QuayPharma</p> <p>www.quaypharma.com</p>	<p>Description: Quay are world renowned for our formulation development and clinical manufacturing, and our understanding of poor soluble and bioavailable small molecules, plus our formulation development and clinical services include:</p>	<ul style="list-style-type: none"> • Immediate release and controlled release tablets. • Multilayer tablets. • Immediate release capsules. • Oral multi particulates such as beads, pellets and mini-tablets. • Liquid and semi-solid filled capsules. • Fast dispersible tablets. • Coating of tablets, capsules and pellets. • Micro-encapsulation using spray drying. • Oral liquids and suspensions.


Name	About	Assets
 www.randox.com	<p>Keywords: Disease management, Diagnostics, Pharma services, Customer assay, Biosciences, Antibodies, Bioreagents, Immunoassay, Quality control, Reagents, Chemistry, Molecular, Life sciences, Precision medicine, CDx, Companion diagnostics, Point of care.</p> <p>Description: Offer revolutionary products and solutions to provide more efficient, higher quality, and reliable diagnostics in the widest variety of laboratory settings. As a world leader in the in-vitro diagnostics industry with over 35 years' experience, Randox products offer clinicians and physicians the most comprehensive insight into patient diagnosis allowing for more effective disease management and treatment.</p>	




Keywords:
Market access, Europe, Reimbursement, Pricing, Launch strategy, Consultancy.


Description:
Specialist pharmaceutical pricing and market access consultancy. Remap Consulting supports pharmaceutical and biotech companies in formulating local and global product launch strategies, solves market access challenges and offers training to upskill internal teams in this area. More information on our expertise can be found at www.remapconsulting.com.



Name	About	Assets
 <p>www.sonraianalytics.com</p>	<p>Keywords: Genomics, Proteomics, Bioinformatics, Analytical services, AI and cognitive computing, AI data analytics.</p> <p>Description: Sonrai Analytics works with pharma and biotech companies and CROs. We help them to wrangle, integrate and visualise their data and find patterns using deep learning and AI in order to accelerate drug development and research.</p>	<p>InDRA is Sonrai's cloud-native AI data analytics platform. It provides biotech and pharma companies and CROs with a highly secure, remote-enabled online platform to cleanse, analyse and share large volumes of data.</p>
 <p>www.sygnaturediscovery.com</p>	<p>Keywords: Target validation, Hit identification, Hit-to-lead, Lead optimization, Drug candidate, Library design and synthesis, Fragment-based drug discovery, Computational chemistry, Medicinal chemistry, In-vitro biology, ADME, In-vivo, PK/PD and protein crystallography.</p> <p>Description: Since 2004, Sygnature Discovery has been offering high quality drug discovery services and providing guidance and support to clients for the discovery and development of new medicines.</p>	<p>Since 2011, have delivered 14 drug candidates (Phases I, II and III).</p> <p>Integrated drug discovery capability (Nottingham and Alderley Park, UK).</p> <p>\$40M HQ and research facility, the Discovery Building, in BioCity Nottingham. In September 2017, significant private equity investment in Sygnature by Phoenix Equity Partners. New DMPK facility at Alderley Park, UK from October 2018.</p>


Name	About	Assets
 www.synmedchem.com	<p>Keywords: Synthetic chemistry, Medicinal chemistry, CRO integrated drug discovery.</p> <p>Description: SYNthesis med chem is a chemistry-focussed, contract research organisation that provides custom synthesis, medicinal chemistry and integrated drug discovery services.</p>	<p>In February 2021 SYNthesis med chem entered into a strategic acquisition agreement with Viva Biotech giving SYNthesis access to Viva's structural biology, biological assays and DMPK capabilities. This acquisition means that in addition to both custom synthesis and medicinal chemistry services, SYNthesis is now able to carry out fully integrated drug discovery projects.</p>

Diagnostics

Name	About	Assets
 <p>www.biosignatures.com</p>	<p>Keywords: Early diagnostics, Screens, Clinical diagnostics, Blood tests, Prostate, Bladder, Renal, Cancer, Discovery platform, Analytics software, Machine learning, AI, Proteomics.</p> <p>Description: Diagnostic discovery platform. The first output of this system is a prostate cancer blood test - a single analyte that in an independently blinded validation clinical trial outperforms competitive offerings.</p> <p>Embarking on an ambitious 500,000 sample discovery project to build screens for multiple conditions in cancer and dementia competitive offerings.</p>	<p>Advanced proteomic system and discovery software developed over 18 years measures modified forms of proteins - a key area of disease biology that mainstream proteomic platforms do not measure well.</p> <p>ISO accredited discovery workflows covering the whole discovery process.</p> <p>Clinically validated prostate cancer blood test capable of saving 48% of biopsies for patients in the PSA "grey area".</p>

Name	About	Assets
 www.kinomica.com	<p>Keywords: Proteomics, Phosphoproteomics, Kinases, Preclinical, Clinical, Personalised medicine, Diagnostics, Oncology, Biomarkers, Mass spectrometry, Bioinformatics, LCMSMS, Mode of action, Target discovery, Patient stratification, Drug discovery, Drug development, Kinase inhibitors.</p> <p>Description: Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. We offer KScan™, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage.</p> <p>We offer KScan™ for: (1) improved monitoring of drug molecular efficacy and response (to fully elucidate mode of action and mechanisms of resistance); and (2) discovery of predictive biomarkers for patient selection and stratification in clinical trials. We also offer additional advanced proteomics services, including the assessment of molecular target turnover and target engagement. Kinomica's approach to measuring the phosphorylation signature of proteins, rather than using gene expression, provides a direct snapshot of protein and cell-signalling activity. We have preclinical proof-of-concept data to demonstrate that our game-changing biomarkers predict drug response more accurately than current state-of-the-art gene sequencing.</p>	

Name	About	Assets
 <p>oxford brain diagnostics</p> <p>www.oxfordbraindiagnosics.com</p>	<p>Keywords: Pathology, Imaging, Diagnostics.</p> <p>Description: Development of the Cortical Disarray Measurement (CDM), a core platform technology, initially applied to the diagnosis of Alzheimer's disease.</p>	<p>Potential to be used to identify other brain conditions as the company grows and expands into new markets.</p>
 <p>ProAxis</p> <p>www.proaxis.com</p>	<p>Keywords: Diagnostics, Neutrophil elastase, Proteinase 3, Respiratory, periostin, Bone health, COVID-19, Other protease targets.</p> <p>Description: ProAxis is a commercial Belfast-based diagnostics company, focused on the specific measurement of active protease biomarkers of lung infection and inflammation (neutrophil elastase, proteinase 3), with development programmes in osteoporosis and COVID-19.</p>	<p>ProteaseTag Active Neutrophil Elastase and Proteinase 3 Immunoassays - both registered with European CE mark for use in COPD, bronchiectasis and CF. Neutrophil Elastase point-of-care test (NEATstik) - registered with European CE Mark for use in COPD, bronchiectasis and CF; commercial distribution partner(s) sought.</p>

Name	About	Assets
 www.randox.com	<p>Keywords: Disease management, Diagnostics, Pharma services, Customer assay, Biosciences, Antibodies, Bioreagents, Immunoassay, Quality control, Reagents, Chemistry, Molecular, Life sciences, Precision medicine, CDx, Companion diagnostics, Point of care.</p> <p>Description: Offer revolutionary products and solutions to provide more efficient, higher quality, and reliable diagnostics in the widest variety of laboratory settings. As a world leader in the in-vitro diagnostics industry with over 35 years' experience, Randox products offer clinicians and physicians the most comprehensive insight into patient diagnosis allowing for more effective disease management and treatment.</p>	



www2.warwick.ac.uk

Keywords:
Technology transfer, Anti-infectives, Antivirals, Women's health, Oncology, Cancer, Drug discovery platforms, Biologics delivery platform, Diabetes, Cryopreservation.

Description:
Clinical-stage nanomedicine
The University of Warwick's (UK), Technology Development and Commercialisation Office.

New Test to Accurately Determine the Onset of Labour.

IVF pre-implantation screening method.

Other opportunities can be found here:

<http://www2.warwick.ac.uk/services/ventures/licensing/licensing-opportunities/>

For more information on the UK's commercial opportunities in life sciences, email lifescience@trade.gov.uk

You can also find out more at great.gov.uk, the government's single destination for information on UK exports, investment, tourism and education.



Department for
International Trade

[great.gov.uk](https://www.great.gov.uk)

The UK's Department for International Trade (DIT) has overall responsibility for promoting UK trade across the world and attracting foreign investment to our economy. We are a specialised government body with responsibility for negotiating international trade policy, supporting business, as well as delivering an outward-looking trade diplomacy strategy.

Disclaimer

Whereas every effort has been made to ensure that the information in this document is accurate the Department for International Trade does not accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned.

© Crown Copyright 2021

You may re-use this publication (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence.

To view this licence visit:

www.nationalarchives.gov.uk/doc/open-government-licence or

email: psi@nationalarchives.gov.uk

Where we have identified any third party copyright information in the material that you wish to use, you will need to obtain permission from the copyright holder(s) concerned.

This document is also available on our website at [gov.uk/dit](https://www.gov.uk/dit)

Any enquiries regarding this publication should be sent to us at enquiries@trade.gov.uk

Published May 2021
by Department for International Trade